口服甲托雷克萨特治疗皮肤填充剂延迟发作的炎症反应
Aesthetic surgery journal. Open forum
|May 1, 2024
概括
低剂量口服甲状腺素 (MTX) 在一项回顾性研究中有效治疗了对皮肤填充剂的反复性延迟发作的炎症反应 (DIRs). 这种方法提供了一个有希望的替代品,当标准疗法失败了这些具有挑战性的填充物并发症.
科学领域:
- 皮肤病学 皮肤病学
- 审美医学是一种美学医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对皮肤填充剂的延迟发作的炎症反应 (DIR) 在美学实践中是一个治疗挑战.
- 对DIRs的既定疗法,包括抗生素,类固醇和氨酸酶,可以产生不满意的结果.
研究的目的:
- 评估低剂量口服甲状腺素 (MTX) 对治疗反复性DIR的疗效.
- 评估MTX在该患者群体中的安全性和耐受性.
主要方法:
- 用口服MTX治疗的复发性DIR患者的回顾性审查.
- 数据收集包括患者人口统计,填充剂类型,先前的治疗,MTX剂量,持续时间和结果.
- 在整个治疗期间,对不良事件进行了监测.
主要成果:
- 包括13名患有复发性DIR的女性患者,这些患者的反应与酸 (HA),液体注射 (LIS) 和聚甲基甲酸盐 (PMMA) 填充剂有关.
- 在10名患者 (77%) 观察到对MTX的完整反应,其中1名 (8%) 的部分反应和2名 (15%) 的不满意反应.
- 平均MTX剂量为12.1mg/周,治疗持续时间为2-3个月,治疗一般耐受良好.
结论:
- 低剂量口服甲醇是一种可行的治疗选择,用于对标准疗法耐药的DIRs.
- MTX的有希望的疗效和耐受性表明其在管理复杂的填充剂相关炎症方面的潜在作用.
- 需要进一步的前性研究来验证这些发现.
更多相关视频
相关概念视频
01:17Phase II Reactions: Methylation Reactions
180
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
180
01:22Drug Delivery: Miscellaneous Routes
338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
279
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
279